Literature DB >> 16313233

Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies.

Sergio A Galindo-Rodriguez1, Eric Allemann, Hatem Fessi, Eric Doelker.   

Abstract

Oral drug delivery is the preferred route of administration of drugs. Because of their versatility, nanoparticles often have been investigated for the delivery of a wide number of drugs by this route. This article first examines the physicochemical, pharmaceutical and technological aspects that make nanoparticles a potential oral delivery system for drugs and active biomolecules. Next, upon consideration of in vivo studies, the pharmacokinetic, pharmacological and therapeutic aspects of orally administered nanoparticles are described. Special emphasis is placed on improvement of oral bioavailability of drugs incorporated into nanoparticles. Two main mechanisms involved in enhancing drug absorption are discussed: the protection of drug by nanoparticles against harsh conditions in the gut and the prolongation of gastrointestinal transit of nanoparticles by using bioadhesive polymers. Furthermore, nanoparticle uptake by intestinal cells and oral vaccination by these colloidal carriers are also covered. In this context, the immune responses elicited as well as the protection against pathogens induced by antigen-loaded nanoparticles administered by the oral route are presented. Finally, the main limitations and perspectives of these colloidal carriers as oral drug delivery systems are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313233     DOI: 10.1615/critrevtherdrugcarriersyst.v22.i5.10

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  37 in total

1.  The counterbalanced effect of size and surface properties of chitosan-coated poly(isobutylcyanoacrylate) nanoparticles on mucoadhesion due to pluronic F68 addition.

Authors:  Bénédicte Petit; Kawthar Bouchemal; Christine Vauthier; Madeleine Djabourov; Gilles Ponchel
Journal:  Pharm Res       Date:  2011-12-07       Impact factor: 4.200

2.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

Review 3.  Oral bioavailability: issues and solutions via nanoformulations.

Authors:  Kamla Pathak; Smita Raghuvanshi
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

Review 4.  Polymeric nanoparticle drug delivery technologies for oral delivery applications.

Authors:  Eric M Pridgen; Frank Alexis; Omid C Farokhzad
Journal:  Expert Opin Drug Deliv       Date:  2015-03-26       Impact factor: 6.648

Review 5.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.

Authors:  Laura M Ensign; Richard Cone; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2011-12-24       Impact factor: 15.470

6.  Role of nanoparticle size, shape and surface chemistry in oral drug delivery.

Authors:  Amrita Banerjee; Jianping Qi; Rohan Gogoi; Jessica Wong; Samir Mitragotri
Journal:  J Control Release       Date:  2016-07-30       Impact factor: 9.776

7.  Alginate/chitosan nanoparticles are effective for oral insulin delivery.

Authors:  B Sarmento; A Ribeiro; F Veiga; P Sampaio; R Neufeld; D Ferreira
Journal:  Pharm Res       Date:  2007-06-19       Impact factor: 4.200

8.  Lyophilized oral sustained release polymeric nanoparticles of nateglinide.

Authors:  Mohammad Kaleemuddin; Prathima Srinivas
Journal:  AAPS PharmSciTech       Date:  2012-12-11       Impact factor: 3.246

Review 9.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

10.  A comparative study on effect of metformin and metformin-conjugated nanotubes on blood glucose homeostasis in diabetic rats.

Authors:  Naser Mirazi; Jamileh Shoaei; Ardeshir Khazaei; Abdolkarim Hosseini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-27       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.